Vimizim is an enzyme replacement therapy that was approved by the FDA in 2014 for the treatment of Mucopolysaccharidosis type IVA, also known as MPS IVA or Morquio A syndrome. MPS IVA is a rare, genetic lysosomal storage disease. Pathogenic mutations of the GALNS gene cause the enzyme N-acetylgalactosamine-6-sulfatase (GALNS) to be deficient or absent. Normally this lysosomal enzyme breaks down glycosaminoglycans (GAGs) (previously known as mucopolysaccharides) but when it is reduced in MPS IVA, the GAG substrates keratan sulfate (KS) and chondroitin-6-sulfate (C6S) accumulate throughout the body to cause cellular, tissue, and organ dysfunction, notably skeletal deformities. Vimizim provides an exogenous source of N-acetylgalactosamine-6-sulfatase.

Vimizim (elosulfase alfa) will be considered for coverage when the following criteria are met:

**Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome)**

For **initial** authorization:
1. Medication must be prescribed by or in consultation with a geneticist, metabolic specialist, or pediatrician experienced with managing mucopolysaccharidoses; AND
2. Member has a diagnosis of MPS IVA confirmed by at least one of the following:
   a) Low GALNS enzyme activity AND normal activity of a second sulfatase (to exclude Multiple Sulfatase Deficiency), and/or
   b) Molecular genetic testing identifies pathogenic GALNS gene mutations; AND
3. Documentation of baseline urinary KS (uKS) level.
4. **Dosage allowed/Quantity limit:** 2 mg/kg IV infusion once weekly

*If all the above requirements are met, the medication will be approved for 6 months.*

For **reauthorization**:
1. Chart notes must show improvement or stabilized signs and symptoms of disease such as improved endurance (e.g., 6-minute walk test) and/or reduced uKS levels.

*If all the above requirements are met, the medication will be approved for an additional 12 months.*

CareSource considers Vimizim (elosulfase alfa) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.
References:


Effective date: 01/01/2022
Revised date: 07/20/2021